Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801929 | 0.96 | GRB2 (0.51) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL31039951 | 0.93 | OPRM1 (0.56) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL29802247 | 0.93 | NTSR2 (0.49) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL29802139 | 0.93 | F2 (0.49) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL29802410 | 0.92 | ACE (0.49) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL29571627 | 0.91 | NRP1 (0.54) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL30997450 | 0.91 | GRB2 (0.55) | NRP1F2NTSR2NTSR1SORT1 | |
| SCHEMBL29802012 | 0.91 | ACE (0.48) | NRP1F2NTSR2NTSR1OPRM1 | |
| SCHEMBL31519056 | 0.91 | F2 (0.58) | F2NTSR2NTSR1SORT1DPP4 | |
| SCHEMBL8601713 | 0.91 | DPP7 (0.53) | NRP1F2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306534-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | Wuhan Innerse Pharmaceutical Inc. (CN) | 2024-01-17 | — | — | EP | disclosed |
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022188878-A1 | MULTIFUNCTIONAL POLYPEPTIDE AND APPLICATION THEREOF IN FIELD OF MEDICINES | 武汉英纳氏药业有限公司 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | NRP1 2622/4885F2 3/4885NTSR2 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.